Thursday, June 27, 2019 07:54 PM

FDA OKS 1ST DRUG FOR SINUSITIS WITH NASAL POLYPS

THURSDAY, June 27, 2019 (HealthDay News) -- In what specialists say could be a turning point in care, the U.S. Food and Drug Administration on Wednesday approved the first drug to treat chronic sinusitis[1] that involves the growth of polyps within the sinuses[2].

Dupixent[3] (dupilumab) is given by injection every two weeks. It was approved to treat patients with nasal polyps[4] and chronic rhinosinusitis -- defined as a prolonged inflammation[5] of the sinuses[6] and nasal cavity, the FDA said.

"Nasal polyps can lead to loss of smell and often patients require surgery to remove the polyps," explained the FDA's Dr. Sally Seymour in an agency news release.

"Dupixent provides an important treatment option for patients whose nasal polyps are not adequately controlled with intranasal

News source: WebMD

See also: Nashville ENT